Register Login

Sarepta Therapeutics Inc (SRPT)

(10% Negative) Sarepta Therapeutics Inc (SRPT) Announces Delay in revenue Trials for San Francisco Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 7:42 p.m.

    📋 Sarepta Therapeutics Inc (SRPT) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 12:05:31

    Event Type: Clinical Trial Update

    Event Details:

    Sarepta Therapeutics Inc (SRPT) Announces Clinical Trial Update Sarepta Therapeutics Inc (SRPT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: revenue, million
    • Diseases/Conditions: San Francisco, ELEVIDYS totaled $110
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: PMO
    • Updated Timeline: Fourth Quarter and Full-Year 2025, full-year 2025

    🔬 Clinical Development Pipeline (Sarepta Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    delandistrogene moxeparvovec GENETIC Phase PHASE1 Muscular Dystrophy, Duchenne ClinicalTrials.gov
    Corticosteroid DRUG Phase PHASE3 Muscular Dystrophies, Limb-Girdle ClinicalTrials.gov
    SRP-9003 GENETIC Phase PHASE1 Limb-Girdle Muscular Dystrophy, Type 2E ClinicalTrials.gov
    Standard of Care DRUG Preclinical Duchenne Muscular Dystrophy ClinicalTrials.gov
    imlifidase BIOLOGICAL Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Duchenne Muscular Dystrophy ClinicalTrials.gov
    SRP-4053 DRUG Phase PHASE3 Duchenne Muscular Dystrophy ClinicalTrials.gov
    SRP-4045 DRUG Phase PHASE3 Duchenne Muscular Dystrophy ClinicalTrials.gov
    RESTEN-MP DRUG Phase PHASE2 Coronary Artery Disease ClinicalTrials.gov
    AVI-4126 Injection (RESTEN-NG®) DRUG Phase PHASE1 Neoplasms ClinicalTrials.gov
    AVI-4065 Injection DRUG Phase PHASE1 Encephalitis ClinicalTrials.gov
    AVI-4020 Injection DRUG Phase PHASE1 West Nile Virus ClinicalTrials.gov
    AVI-5126 DRUG Phase PHASE2 Cardiovascular Disease ClinicalTrials.gov
    AVI-6002 DRUG Phase PHASE1 Ebola Hemorrhagic Fever ClinicalTrials.gov
    Normal Saline Solution (NSS) OTHER Phase PHASE1 Ebola Hemorrhagic Fever ClinicalTrials.gov
    AVI-7537 DRUG Phase PHASE1 Ebola Hemorrhagic Fever ClinicalTrials.gov
    AVI-7100 DRUG Phase PHASE1 Influenza ClinicalTrials.gov
    AVI-6003 DRUG Phase PHASE1 Marburg Hemorrhagic Fever ClinicalTrials.gov
    AVI-7288 DRUG Phase PHASE1 Marburg Hemorrhagic Fever ClinicalTrials.gov
    AVI-4658 for Injection DRUG Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    AVI-4658 (Eteplirsen) DRUG Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Eteplirsen DRUG Phase PHASE2 Muscular Dystrophy, Duchenne ClinicalTrials.gov
    AVI-4658 (PMO) DRUG Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    rAAVrh74.MHCK7.DYSF.DV DRUG Phase PHASE1 Dysferlinopathy ClinicalTrials.gov
    Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] DRUG Phase PHASE4 Duchenne Muscular Dystrophy ClinicalTrials.gov
    SRP-5051 DRUG Phase PHASE1 Muscular Dystrophy, Duchenne ClinicalTrials.gov
    SRP-9004 GENETIC Phase PHASE1 Limb-Girdle Muscular Dystrophy, Type 2D ClinicalTrials.gov
    Vyondys 53 DRUG Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Exondys 51 DRUG Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Amondys 45 DRUG Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Classical conditioning task BEHAVIORAL Preclinical DMD ClinicalTrials.gov
    Vesleteplirsen DRUG Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Golodirsen DRUG Phase PHASE3 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Casimersen DRUG Phase PHASE3 Duchenne Muscular Dystrophy ClinicalTrials.gov
    SRP-6004 GENETIC Phase PHASE1 Limb Girdle Muscular Dystrophy ClinicalTrials.gov
    SRP-9005 BIOLOGICAL Phase PHASE3 Muscular Dystrophies, Limb-Girdle ClinicalTrials.gov
    Plasmapheresis PROCEDURE Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    Glucocorticoid DRUG Phase PHASE3 Limb-girdle Muscular Dystrophy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Sarepta Therapeutics Inc
    • Ticker Symbol: SRPT

Search

News categories